As2O3
Showing 26 - 50 of >10,000
MDD With Anxious Distress Trial in Worldwide (JNJ-61393215, Placebo)
Completed
- Major Depressive Disorder With Anxious Distress
- JNJ-61393215
- Placebo
-
Garden Grove, California
- +34 more
Sep 2, 2022
Crohn's Disease Trial in Worldwide (PF-06651600 Placebo, PF-06651600, Placebo PF-06700841)
Active, not recruiting
- Crohn's Disease
- PF-06651600 Placebo
- +3 more
-
Dothan, Alabama
- +187 more
Aug 17, 2022
Sarcopenia Trial in Wageningen (Vegan diet (intervention), Omnivorous diet (control))
Recruiting
- Sarcopenia
- Vegan diet (intervention)
- Omnivorous diet (control)
-
Wageningen, Gelderland, NetherlandsWageningen University and Research
Dec 1, 2022
Depth of Sedation and Its Impact on Cerebrovascular Reactivity
Not yet recruiting
- ARDS, Human
- Masimo O3 NIRS cerebral oximetry and SedLine processed EEG
-
Winnipeg, Manitoba, CanadaUniversity of Manitoba
Apr 27, 2023
Spondylitis, Ankylosing Trial in Worldwide (CC-99677, Placebo)
Active, not recruiting
- Spondylitis, Ankylosing
- CC-99677
- Placebo
-
Flagstaff, Arizona
- +139 more
Dec 9, 2022
Schizophrenia Trial in Worldwide (Pimavanserin, Placebo)
Recruiting
- Schizophrenia
- Pimavanserin
- Placebo
-
Ciudad Autonoma Buenos Aires, Argentina
- +82 more
Oct 14, 2021
Knee Osteoarthritis Trial in Ankara (Medical ozone injection, steroid injection group)
Recruiting
- Knee Osteoarthritis
- Medical ozone injection
- steroid injection group
-
Ankara, TurkeySefa
Mar 15, 2022
Postmenopausal Osteoporosis Trial in Worldwide (FKS518, US-licensed Prolia)
Active, not recruiting
- Postmenopausal Osteoporosis
- FKS518
- US-licensed Prolia
-
Sofia, Sofia City, Bulgaria
- +75 more
Aug 29, 2022
Depressive Disorder, Major Trial in Worldwide (Seltorexant, Matching to Seltorexant, Quetiapine XR)
Recruiting
- Depressive Disorder, Major
- Seltorexant
- +3 more
-
Birmingham, Alabama
- +212 more
Jul 20, 2022
Esophageal Adenocarcinoma Trial in Buffalo (Carboplatin, 3 Dimensional Conformal Radiation Therapy, Propranolol)
Recruiting
- Esophageal Adenocarcinoma
- Carboplatin
- +4 more
-
Buffalo, New YorkRoswell Park Cancer Institute
Aug 3, 2022
Acute Myeloid Leukemia, Acute Myeloid Leukemia Recurrent, Leukemia Trial in Boston (Cytokine-Induced Memory-like Natural Killer
Not yet recruiting
- Acute Myeloid Leukemia
- +3 more
- Cytokine-Induced Memory-like Natural Killer Cells
- +2 more
-
Boston, Massachusetts
- +1 more
Nov 22, 2023
Pseudomonas Aeruginosa Pneumonia Trial in Worldwide (AR-105, Placebo)
Completed
- Pseudomonas Aeruginosa Pneumonia
- AR-105
- Placebo
-
Sacramento, California
- +110 more
Mar 8, 2022
Relapsing-Remitting Multiple Sclerosis (RRMS) Trial in Worldwide (IMU-838 (30 mg/day), IMU-838 (45 mg/day), Placebo)
Active, not recruiting
- Relapsing-Remitting Multiple Sclerosis (RRMS)
- IMU-838 (30 mg/day)
- +3 more
-
Blagoevgrad, Bulgaria
- +37 more
Jan 19, 2022
Depressive Disorder, Major, Anhedonia Trial in Worldwide (Aticaprant, Placebo)
Recruiting
- Depressive Disorder, Major
- Anhedonia
- Aticaprant
- Placebo
-
Birmingham, Alabama
- +156 more
Jan 31, 2023
HER-2 Positive Advanced Solid Tumors Trial (D3L-001)
Not yet recruiting
- HER-2 Positive Advanced Solid Tumors
- D3L-001
- (no location specified)
Jul 20, 2023
Myofascial Pain Syndrome, Myofascial Trigger Point Pain Trial in Ankara (Ozone therapy, Lidocaine injection group)
Completed
- Myofascial Pain Syndrome
- Myofascial Trigger Point Pain
- Ozone therapy
- Lidocaine injection group
-
Ankara, TurkeyGaziler Physical Medicine and Rehabilitation Education and Resea
Jan 14, 2022
Basal Cell Carcinoma, Squamous Cell Carcinoma of Skin Differentiated Trial in London (Hydrogen Peroxide 30 % Topical Solution)
Recruiting
- Basal Cell Carcinoma
- Squamous Cell Carcinoma of Skin Differentiated
- Hydrogen Peroxide 30 % Topical Solution
-
London, Ontario, CanadaLondon Regional Cancer Program
Aug 29, 2022
Skin Manifestations Trial in Jakarta Pusat (Sodium Bicarbonate (NaHCO3) Plus Solution, Water (H2o))
Completed
- Skin Manifestations
- Sodium Bicarbonate (NaHCO3) Plus Solution
- Water (H2o)
-
Jakarta Pusat, DKI Jakarta, Indonesiadr. Cipto Mangunkusumo General Central National Hospital
Apr 10, 2020
Diabetes, Type 2 Diabetes Trial in Worldwide (LY3209590, Insulin Degludec)
Recruiting
- Diabetes
- Type 2 Diabetes
- LY3209590
- Insulin Degludec
-
Escondido, California
- +128 more
Jan 18, 2023
Healthy Trial in Nottingham (BI 685509 oral formulation prototypes, BI 685509 standard oral formulation)
Completed
- Healthy
- R1: Reference Product X
- +12 more
-
Nottingham, United KingdomQuotient Sciences
Dec 7, 2022
SARS-CoV-2 Pneumonia Trial in Durham (Ozone)
Not yet recruiting
- SARS-CoV-2 Pneumonia
-
Durham, North CarolinaDuke University Medical Center
Mar 3, 2023
Advanced Cholangiocarcinoma, FGFR2 Gene Rearrangements Trial in Worldwide (TAS-120, Cisplatin/Gemcitabine)
Active, not recruiting
- Advanced Cholangiocarcinoma
- FGFR2 Gene Rearrangements
-
Albuquerque, New Mexico
- +100 more
Feb 1, 2023